Physician profile
Meenakshi Jain
NPI 1467409037
$35,371.97
in general payments reported to CMS, 2019-2025
35 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $1,572 · 2021: $2,059 · 2022: $2,276 · 2023: $6,941 · 2024: $2,696 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $25K · Food and Beverage: $2,405 · Travel and Lodging: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $25,099.00 |
| Food and Beverage | $2,405.37 |
| Travel and Lodging | $625.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $30,978.48 | 2019-2025 | Da Vinci Surgical System |
| Axonics, INC. | $1,684.29 | 2020-2024 | Axonics, Bulkamid |
| Abbvie INC. | $417.58 | 2020-2025 | |
| Astellas Pharma US INC | $383.09 | 2019-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $226.72 | 2020-2024 | Slynd, Tyblume |
| Millicent US INC | $192.62 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Mayne Pharma Commercial LLC | $171.31 | 2022-2025 | |
| Boston Scientific Corporation | $142.15 | 2025 | Axonics |
| Pfizer INC. | $137.89 | 2019-2023 | |
| Femselect INC. | $119.98 | 2024 | Enplace |
| Myovant Sciences INC. | $110.64 | 2021-2022 | |
| Allergan, INC. | $85.45 | 2019 | |
| Therapeuticsmd, INC. | $64.21 | 2019-2021 | |
| Avion Pharmaceuticals | $57.34 | 2022-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $54.46 | 2023 | Myfembree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $52.85 | 2022-2024 | |
| Medtronic USA, INC. | $51.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $49.78 | 2019-2020 | |
| Coloplast Corp | $40.77 | 2021-2025 | |
| Shield Therapeutics INC | $38.23 | 2024 | |
| Evofem Biosciences, INC. | $33.77 | 2021 | |
| Vertical Pharmaceuticals, LLC | $31.80 | 2019 | |
| Medtronic, INC. | $29.74 | 2023-2024 | Truclear, Interstim |
| Channel Medsystems, INC. | $27.17 | 2023 | |
| Dysis Medical, INC. | $25.70 | 2020 | |
| Mimedx Group, INC. | $22.90 | 2025 | |
| Amgen INC. | $20.00 | 2020 | |
| Conmed Corporation | $19.66 | 2021 | |
| Integra Lifesciences Corporation | $18.15 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Exact Sciences Corporation | $17.57 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $16.52 | 2020 | |
| Gynesonics, INC. | $13.72 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $12.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.17 | 2021 | |
| Mission Pharmacal Company | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meenakshi Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.